Member Info for gameangler

Before ezutromid was pulled posters were saying that Summit share cap was covered by the their antibiotics prospects. When I made a small initial investment subsequent to Serepta coming on board it looked an attractive risk/reward for a potential blockbuster with a margin of safety in their antibiotic activity.

Phase 2 is a graveyard for many drug trials, therefore I prefer to invest after the trial is successful. In view of the enthusiastic 24 week progress RNS highlighting positive indications, l trebled my holding and within a few weeks 80% of the share value had evaporated.

Taking a step back and looking at Summit
It is a pure play antibiotics developer with a Phase 3 ready urgently required prospect.
In a market sector that has limited competition.
Regulators and governments are starting to offer generous incentives to developers of new classes of antibiotics.
It has Discuva a unique antibiotic screening platform.

As a stand-alone investment it has enough things going for it for me to have bought 35k shares below 40p

Great post thanks for finding it.
If this Bill passes then the transferable vouchers would be highly valued by a major pharma co. To extend a blockbuster drug exclusivity by a year could be worth at a guess up to $1bn and Summit potentially have 2 candidates that could fit the bill.

I have posted it on Seeking Alpha to alert US investors.

Thanks for your informative post, things appear to be looking on track for a positive outcome for BMR, GLR and JLP shareholders. The potential rewards are staggering compared with their respective Mkt Caps.

https://www.youtube.com/watch?v=4GHMO8ne6PY

1)Looks like a lot of excellent opportunities developing for affirmers. Currently insufficient cash to take everything forward.

2)They expect to move some products from research to commercialisation in next 6-18 months. Still lots of R&D expenditure needed accross these new fields of use and only £6m cash at year end ( 31st July 2018). If no upfront cash deal in next 9 months (eg Moderna) they will need a fund raise.

3)Top drawer Chairman has joined the Board which is reassuring that their products are potentially highly valuable.

4) If they avoid a heavily diluting fund raise, their shares could be stunningly cheap with current mkt cap of £20m.

Buyers seem to be holding off until the picture becomes clearer. It means even small sales volume is pounding the share price.

https://www.xconomy.com/boston/2018/06/19/sareptas-data-are-first-in-rush-for-duchenne-gene-therapy/

In case you haven't seen this http://www.amerisurresources.com/images/rns-pdfs/AGM-Presentation-15-05-18.pdf

Totally agree with JTD's comments on immediate programme of share buybacks being a no-brainer. Strong cash and background seller means it is the best value creation route for shareholders.

YorkshireLife On purchasing I had the same initial views of wow!! under valued share here. It has since fallen 20%, but the comfort is, it could be even more undervalued???? Long term holders remain hopeful, though we have a history of disappointments. I do not like criticisms of BOD as it is a difficult job, but you can accept disappointments if they are adequately explained. They advised shareholders during 2017 in Company Presentations and News releases that there were aiming for sustainable production in excess of 7,000 bopd by year end. They managed only some daily peak flows in Dec17 but not for the month. Since then they have failed to live up to their guidance given to shareholders. With no adequate explanation, the share price naturally fell, and institution and private shareholders could understandably uncertain how trustworthy guidance from the board is. For info an extract repeat from my posting at the time...... Interim's Presentation 25 Sept 17 stated they were targeting a 2017 exit production of 7,000+ bopd Output update RNS on 4 Dec 17 stated.......'The company is expecting a sustainable year end exit rate of production in excess of 7,000 bopd'....... Well sustainability didn't last long!!!! Given there is a large Board of Directors, I would expect at least one of them to query if the shareholders are being given what appears to be misleading statements. Workovers can be needed for a variety of different reasons. In my experience they were either planned or emergency/urgent. The questions I would like answered are: 1) Their statement seems to imply there is more than one workover/treatments, if so how many and how frequent? 2) Were these planned workovers deferred from last year to meet the year end 7,000 bopd target? 3) If they were planned this year why did they state that 7,000 bopd was a sustainable monthly output? 4) If they are unplanned what was the reason for them? Investors naturally do not like uncertainty and I think the Board owe Shareholders some clarity, given the market's reaction.

See BMR Vanadium Update Jan 2017 http://www.lse.co.uk/share-regulatory-news.asp?shareprice=BMR&ArticleCode=3peiqbv1&ArticleHeadline=Vanadium_Update 45,000 t of vanadium pentoxide V2O5 with potential contribution of $952.2m based on $21,000/t ( 9 Dec 2016) On 25th Jan 2018 V2O5 was $12.8/lb an 8 year high (12.8 x 2240 = $28,672/t) and supply situation is tight See https://www.valuewalk.com/2018/01/vanadium-price-8-year-high/ At the end of March 18 MetalBulletin reported China FOB prices of $15.8/lb ( $35,392/t ) This is getting to a level that may be larger than the combined value of all the lead and zinc.

The results need to be viewed in the context of all the upheavals this year. This included major delays by supplier Intel, which led to delayed sales and the substitution by Telit of more expensive modules to fulfil orders. The good news is that these problems are now in the past. Revenue figures are better than I expected and adjusted EBITDA positive, though statutory profit is likely to look pretty horrible. You would expect the new management to produce 'throw in the kitchen sink' figures with every write down they can find. Given they have market leading products R&D must be a major cost. The Chairman's statement looks reassuring that the new management are getting to grips with the stable running of the business and finance functions to support their existing technology and sale strengths.

What I particularly like is the Abbott Director's statement.....'We look forward to the outcomes of the study and the potential opportunity to further collaborate with ANGLE in combining FISH and liquid biopsy in other areas.' They have FISH kits for a lot of cancer types. If using the two products in conjunction with each other is successful it could be a big commercial breakthrough. Abbott will posses a worldwide marketing capability already in place. https://www.molecular.abbott/int/en/products/oncology/all-solid-tumor#Breast_Cancer www.molecular.abbott/int/en/products/oncology/pathvysion-her-2-dna-probe-kit-II

Just back from AGM where they discussed their Trading Update today. The Board were upbeat about the high quality of Senior Management they have been recruiting. This includes a highly experienced Managing Director for the Engineering Division. Engineering They are excited about prospects for USA. The potential market is large for W�lischmiller/STABER equipment if it is manufactured and assembled in the USA and marketed with NuVision products. UK manufacturing activity has bounced back strongly. Agriculture UK is performing well and UK feed blocks are strong. USA feed block sales recovery improving. The new highly efficient Tennessee Plant is serving an new geographical area and already working 24 hrs a day. Continuing feed block growth in NZ with plans for a plant when volume justifies this. Efforts to develop markets in S. America are taking place. Limiting of antibiotics in cattle will mean the need for higher health and nutrition standards. This plays into Carr's strengths Brexit Firstly Carr's serve international markets and more than 50% of their profits are overseas. They are investing to grow these businesses. The current UK government statements are indicating any changes will occur over sufficient time for planning to take place in their implementation. At the end of the meeting all the attendees I spoke to a seemed positive and upbeat for the future. Omerta -For further info on Carr's suggest you look at their website. http://investors.carrsgroup.com/ Presentations/Analyst Coverage

Carr's is a local company and the things I hear about it, first hand, are all positive. Have been a shareholder for 20+ years and seen tremendous growth. Chairman is ex-MD and a shrewd and steady hand. In recent years their sale of two large operations ( Fertilisers and Flour Milling) reduced turnover and earnings, but got handsome prices for mature and low margin business with little growth prospects. Company is well run and well invested in growth of existing operations and the high tech. nuclear/energy sector. It is diversified both in market sectors and geographically. It is exposed to agricultural cycles, currency fluctuations and competitive engineering manufacturing. The two hits last year were USA cattle prices leading to falling feed-block sales (now reversed), and unexpected delays in the start of a manufacturing contract. This may have led to underemployed resources and the taking on of less profitable work to keep highly skilled staff employed. I sleep soundly with this share in my portfolio. The farming and nuclear sectors are more stable that the wider economy hence the low Beta of 0.21. In terms of risks, Brexit is a potential cloud on the horizon for farmers profitability. The EU protectionist food trade tariffs are a barrier unless we get a good trade deal. This is a quiet board as the share seems to be held as a core long term investment, holding rather than short term speculation. The Directors buying looks like a positive endorsement of their view of the future prospects.

Who benefits the most from scare stories and fears https://shorttracker.co.uk/company/GB00B06GM726/

The addition of the early pregnancy testing feature into MyLotus appears to have produced more interest in the product. They are completing the collection of additional patient data by the end of the month. The next step is production of a peer reviewed paper that will be published in a journal. Results will also be presented to interested distributors at a meeting. Its a new product for a unmet need. The data should show how good it is at helping conception. If it looks very good and there is a big sign up of distributors, we may hopefully see some positive share price movement in the next few months. http://www.stocktube.com/video/8241/concepta-secures-two-additional-mylotus-distribution-agreements-in-china-8241.html

Agreed re shares in issue and thhe level of support of Funding Knight will continue to be an ongoing concern for this year. Down the road there appears potential for fintech to grow with a low cost structure. The big banks are apparently now lending more,but they are disadvantaged by higher costs.

Try this:- https://www.rns-pdf.londonstockexchange.com/rns/5701A_-2017-3-27.pdf

Quick maths check, (https://www.rns-pdf.londonstockexchange.com/rns/5701A_-2017-3-27.pdf) page 27 Notes to Financial Statements. Total assets £142m less goodwill (£25m) and all liabilities (£51m) gives approx NAV of £66m, at year end. Av. weighted shares outstanding at year end 270,934,270 so NAV per share 24.36p Of the £66m, Fintech Ventures is £41m which is 62% of NAV or 15.13p. Of this £41m, only £5m are loans, cash and receivables. The rest is investment in the FinTech platforms. Must say the company report and accounts are really hard going, it is all very complicated and difficult for PI's to follow. This used to be a very profitable company with substantial asset backing. We have to hope that the management and execution is to notch to deliver some strong value growth from heavy investments in the Fintech Ventures.

10 March 10.96% short - share price 309p 13 March Final Results 21 March 10.12% short - share price 322p 24 march %shot not reported yet - share price 333p Early days but could contribute to some sharp daily rises, worth watching. http://shorttracker.co.uk/company/GB00B06GM726/all

Firstly a historical post that sets the scene for why Telit is in front of a tsunami growth market. It has only ever acquired for IP and not for revenue. It is promoted as uniquely positioned with its in house technology across a range of IOT sectors as the best pure play IOT share. http://seekingalpha.com/article/955671-finding-monopoly-potential-in-telit-a-machine-to-machine-m2m-technology-company A wannabee : http://seekingalpha.com/article/4021514-sierra-wireless-new-direction-getting-established http://seekingalpha.com/article/4010701-sell-sierra-wireless-buy-instead